Head-to-head evidence

BCMA-CART (Bioray Laboratories) vs Idecabtagene vicleucel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

💬 Discuss in AI Terminal →

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

BCMA-CART (Bioray Laboratories)

Developed by BioRay Laboratories (Shanghai Bangyao Biotechnology Co., Ltd.)

Phase 1/2 in Multiple MyelomaCAR-T cell therapy

not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2028 · NCT07169500 (registry estimate)

Unlock with Research ↗

Idecabtagene vicleucel

Marketed by Bristol-Myers Squibb

Approved in Multiple Myelomacell therapy (autologous CAR-T)

Reliable signal

NCT03651128 · Phase 3 · completed

Randomized, open-label Phase 3 trial (n=386) demonstrating significant improvement in PFS vs standard regimens in relapsed/refractory multiple myeloma (NEJM 2023).

Next expected readout: May 2027 · NCT05393804 (registry estimate)

Unlock with Research ↗

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCMA-CART (Bioray Laboratories)'s landscape · Idecabtagene vicleucel's landscape